Next-generation endocrine therapy in HR+/HER2 - breast cancer: oral SERDs, ER-targeting innovations, and ctDNA-driven ESR1 mutation-guided switching
{{output}}
Background: Endocrine therapy (ET) is the backbone of HR+/HER2 - breast cancer management, yet acquired resistance commonly emerges despite aromatase inhibitors (AIs) and CDK4/6 inhibitors. A key actionable mechanism is treatment... ...
